Navigation Links
Optimer Pharmaceuticals Appoints Eric Sirota as Chief Operating Officer
Date:5/13/2013

rketing solutions that enhance brand revenue, drive efficiency and lower costs.  Prior to June 2009, Mr. Sirota served as an executive of Pfizer Inc., most recently as Vice President of Pfizer's US Marketing, Commercial Strategy and Innovation and Regional Sales, responsible for the neuroscience and pain franchises.  During his over twenty-year career at Pfizer, Mr. Sirota was responsible for 12 therapeutic areas and more than 25 brands,  including anti-infectives.  He received his B.S. degree in Pharmacy from Rutgers College of Pharmacy and his Master of Business Administration degree from The Wharton School, The University of Pennsylvania.

About Optimer Pharmaceuticals

We are a global biopharmaceutical company currently focused on commercializing our antibiotic product DIFICID® (fidaxomicin) tablets in the United States and Canada, and developing other fidaxomicin products in the United States and worldwide, both by ourselves and with our partners and licensees. DIFICID, a macrolide antibacterial drug, was approved by the U.S. Food and Drug Administration on May 27, 2011, for the treatment of Clostridium difficile-associated diarrhea, or CDAD, in adults 18 years of age and older. Fidaxomicin has also received marketing authorization in other jurisdictions, including the European Union, where it is marketed under the trade name DIFICLIR™ by our licensee, Astellas Pharma Europe. CDAD is the most common symptom of Clostridium difficile infection, or CDI. Additional information can be found at http://www.optimerpharma.com.

Forward-looking Statements

Statements included in this press release that are not a description of historical facts are forward-looking statements, including, without limitation, statements related to future roles and contributions of Mr. Sirota at Optimer.
'/>"/>

SOURCE Optimer Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Optimer Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
2. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
3. Optimer Pharmaceuticals and Specialised Therapeutics Australia Collaborate to Commercialize Fidaxomicin for Clostridium difficile Infection in Australia and New Zealand
4. Optimer Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
5. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2012 Financial Results
6. Optimer Pharmaceuticals Appoints Stephen Newman to Its Board of Directors
7. Optimer Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
8. Optimer Pharmaceuticals to Present at September 2012 Investor Conferences
9. Optimer Pharmaceuticals Reports Third Quarter 2012 Financial Results
10. Optimer Pharmaceuticals to Present at November 2012 Investor Conferences
11. Optimer Pharmaceuticals to Present at 23rd Annual Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... May 1, 2015  Legendary actor and director ... new PBAFacts campaign designed to educate and encourage patients ... about Pseudobulbar Affect (PBA) and to speak with their ... actor has the ability to cry and laugh on ... control experienced by people living with PBA episodes. ...
(Date:5/1/2015)... Semler Scientific, Inc. (Nasdaq: SMLR ), ... and markets products that assist healthcare providers in monitoring ... for the first quarter ended March 31, 2015. ... reported continued progress with year over year growth of ... 14%," said Doug Murphy-Chutorian , M.D., chief executive ...
(Date:5/1/2015)... -- Cambrex Corporation (NYSE: CBM ) reports results for ... Highlights , Sales increased 18% compared to the ... impact, driven by Innovator products and Controlled Substances. , ... first quarter of 2014. , GAAP Diluted EPS from ... last year and Adjusted Diluted EPS was $0.29 compared to ...
Breaking Medicine Technology:Danny Glover Joins PBA Facts Campaign, to Educate and Build Awareness of Pseudobulbar Affect (PBA), a Little Known but Widespread Neurologic Condition 2Danny Glover Joins PBA Facts Campaign, to Educate and Build Awareness of Pseudobulbar Affect (PBA), a Little Known but Widespread Neurologic Condition 3Semler Reports First Quarter 2015 Financial Results 2Semler Reports First Quarter 2015 Financial Results 3Semler Reports First Quarter 2015 Financial Results 4Semler Reports First Quarter 2015 Financial Results 5Cambrex Reports First Quarter 2015 Financial Results 2Cambrex Reports First Quarter 2015 Financial Results 3Cambrex Reports First Quarter 2015 Financial Results 4Cambrex Reports First Quarter 2015 Financial Results 5Cambrex Reports First Quarter 2015 Financial Results 6Cambrex Reports First Quarter 2015 Financial Results 7Cambrex Reports First Quarter 2015 Financial Results 8Cambrex Reports First Quarter 2015 Financial Results 9Cambrex Reports First Quarter 2015 Financial Results 10Cambrex Reports First Quarter 2015 Financial Results 11
... 8 Nektar,Therapeutics (Nasdaq: NKTR ) today ... program to evaluate NKTR-102 (PEG-irinotecan) as a,potential treatment ... using the company,s innovative small molecule,PEGylation technology platform., ... for NKTR-102 in colorectal cancer is,a major achievement ...
... Trial Data and Emerging Clinical Practice Experience Support ... HYLENEX Efficacy ... Therapeutics, Inc.,(Nasdaq: HALO ), a biopharmaceutical company developing and ... publication of the INFUSE-LR clinical trial results in the Journal,of ...
Cached Medicine Technology:Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer 2Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer 3Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer 4Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 2Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 3Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 4Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 5
(Date:5/3/2015)... (PRWEB) May 03, 2015 “ BolehVPN ” ... Report, which features the latest and coolest technology products available ... for NewsWatch, conducted the review and shared with viewers how ... everyone does these days is on computers and even more ... families and meet people all over the world. In terms ...
(Date:5/3/2015)... It is not too late to register to take part in ... Anne Been in Arnold, Missouri on May 9, 2015. Family ... her loving memory. It has benefited the renowned Brain Aneurysm Foundation ... Lissa suffered a brain aneurysm . After two operations and ... is designed to serve as a remembrance of her and to ...
(Date:5/2/2015)... 2015 Vancouver fencing company, QS Fencing, has ... advice to prospective clients related to their questions on railings ... railings around their decks and patios. While that seems like ... up once the person rolls up their sleeve to start ... railing in finding a gate that matches it. , Instead ...
(Date:5/2/2015)... 2015 We are pleased to announce ... Center as one of the Top Workplaces of 2015. ... addiction treatment field for their ethics and standards of ... to continue their educational efforts. The Delray Recovery Center ... forgetting their purpose – to help individuals heal from ...
(Date:5/2/2015)... May 02, 2015 As a ... issues of the face, neck and décolleté, radiofrequency ... with real potential for the success of vulvovaginal ... ThermiHealth Clinical Advisory Council, ThermiGyn’s Women’s Health Clinical ... ACGE, concluded that ThermiGyn’s temperature controlled radio frequency, ...
Breaking Medicine News(10 mins):Health News:A Method to Keep Private Information Secure was Featured on NewsWatch Television 2Health News:Renowned Brain Aneurysm Foundation to Benefit from Arnold, Missouri’s 3rd Annual Brain Aneurysm Walk in Memory of Lissa Anne Been 2Health News:Professional Staff at QS Fencing Company Now Provides Advice on Railings and Gates 2Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 3
... that enables a surgeon to perform laparoscopic gall bladder and ... computer and video monitor. The surgeon can use hand grips ... arms that can perform the surgery using a variety of ... by Intuitive Surgical, Inc., of Mountain View, Calif., is the ...
... Lung, and Blood Institute (NHLBI) and the National High ... recommendations to treat Hypertension.,Control of systolic blood pressure is ... is a crucial message for health care providers, patients, ... lowering systolic blood pressure to less than 140 mm ...
... from June issue of the American Journal of Epidemiology ... rates than taller people from most causes except cancer. ... women undertaken by Dr.Pekka Jousilahti and his colleagues from ... was found that there was an association between adult ...
... high levels of cholesterol but low levels that are making ... Cholesterol maybe linked to depression and violent behavior. A new ... up to seven times more likely to report symptoms of ... Center in Durham, N.C. Said, "I think that ...
... ,Death Rates Higher for Those Without This Symptom. As many ... or during a heart attack, a study published in The ... diabetics and others who belong to groups likely to have ... such pains. ,The report examined symptoms in more than 400,000 ...
... of the most common cancers in women. If it is ... The Pap smear is the standard screening method for the ... cervical cells. ,Two strains of the human papilloma virus (HPV) ... but not all women who test positive, develop the disease. ...
Cached Medicine News:
... The NIDEK YC-1800 is an ... laser delivery and output technologies, improved ... offset and compact design with versatility ... YC-1800 replaces the YC-1600 and adds ...
... epTIPS Filter have an integrated ... without "self-sealing" additives. This filter provides ... by aerosols, and it does not ... incorrect pipetting. Samples can then be ...
Lightweight PVC housing for easy transport, integrated handle. Easy lamp exchange....
... • V-shaped bottom allows easy ... lips facilitate pour-out ,• Nesting ring ... Solution Basin designed for 4, 8, and ... V-shaped bottom permits withdrawal of practically all ...
Medicine Products: